» Articles » PMID: 36329207

Development, Characterization, and In Vitro Biological Performance of Amphotericin B and Terbinafine Microemulsions Against Leishmania Major

Overview
Journal Curr Microbiol
Specialty Microbiology
Date 2022 Nov 4
PMID 36329207
Authors
Affiliations
Soon will be listed here.
Abstract

This study evaluated the effect of microemulsion (ME) containing Amphotericin B (AmB) alone and associated with Terbinafine (Tbf) on Leishmania major (L. major) using in vitro models. The ME formulations of these drugs were formulated and described. After evaluating their cytotoxicity on the J774A1 macrophage (MΦ), their potency against promastigotes and intracellular amastigotes models was evaluated using an in vitro MTT assay and Giemsa stain, respectively. Based on pseudo ternary phase diagrams, unloaded ME, Tbf-loaded ME (ME-Tbf), and, AmB-loaded ME (ME-AmB) with mean droplet sizes 3.4 ± 0.81, 10.05 ± 0.21, and 8.21 ± 0.46 were successfully prepared, respectively. Concerning toxicity, ME-AmB and ME-Tbf indicated lower toxicity on MΦs compared to the free drugs. The ME formulations showed considerably inhibitory effects compared to the free drug forms when the IC was examined. The IC values of AmB (59.19 ± 1.74 and 36.4 ± 3.2 μg/mL), ME-AmB (7.5 ± 0.9 and 0.8 ± 0.05 μg/mL), Tbf (234.5 ± 9 and 128.8 ± 0.28 μg/mL), ME-Tbf (26.27 ± 0.2 and 11.97 ± 0.6 μg/mL), AmB + Tbf (30.18 and 24.93 μg/mL), and ME-AmB + ME-Tbf (4.79 and 0.37 μg/mL) were estimated after 48 and 72 h, respectively.

Citing Articles

Epoxy-a-lapachone in nanosystem: a prototype drug for leishmaniasis assessed in the binomial BALB/c - Leishmania (Leishmania) amazonensis.

Peixoto J, Goncalves-Oliveira L, Dias-Lopes G, Souza-Silva F, Alves C Mem Inst Oswaldo Cruz. 2024; 119:e240115.

PMID: 39476028 PMC: 11520661. DOI: 10.1590/0074-02760240115.

References
1.
Alvar J, Velez I, Bern C, Herrero M, Desjeux P, Cano J . Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7(5):e35671. PMC: 3365071. DOI: 10.1371/journal.pone.0035671. View

2.
Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S . Cutaneous leishmaniasis. Lancet Infect Dis. 2007; 7(9):581-96. DOI: 10.1016/S1473-3099(07)70209-8. View

3.
Mishra J, Saxena A, Singh S . Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem. 2007; 14(10):1153-69. DOI: 10.2174/092986707780362862. View

4.
Farajzadeh S, Esfandiarpour I, Haghdoost A, Mohammadi S, Mohebbi A, Mohebbi E . Comparison between Combination Therapy of Oral Terbinafine and Cryotherapy versus Systemic Meglumine Antimoniate and Cryotherapy in Cutaneous Leishmaniasis: A Randomized Clinical Trial. Iran J Parasitol. 2015; 10(1):1-8. PMC: 4403527. View

5.
Berman J . Amphotericin B formulations and other drugs for visceral leishmaniasis. Am J Trop Med Hyg. 2014; 92(3):471-473. PMC: 4350529. DOI: 10.4269/ajtmh.14-0743. View